Paul Martin

2.7k total citations
50 papers, 2.2k citations indexed

About

Paul Martin is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Paul Martin has authored 50 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 18 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Paul Martin's work include Lipoproteins and Cardiovascular Health (16 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Drug Transport and Resistance Mechanisms (9 papers). Paul Martin is often cited by papers focused on Lipoproteins and Cardiovascular Health (16 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Drug Transport and Resistance Mechanisms (9 papers). Paul Martin collaborates with scholars based in United Kingdom, United States and Sweden. Paul Martin's co-authors include Dennis W. Schneck, Aaron Dane, Mike J. Warwick, Pat Mitchell, Barry R. Davies, Paul D. Smith, Richard O. Jenkins, Jennifer S. McKay, Mark Cockerill and Armelle Logié and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Cancer Research.

In The Last Decade

Paul Martin

49 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Martin United Kingdom	25	799	705	570	383	268	50	2.2k
Vikram Sinha United States	27	669 0.8×	422 0.6×	469 0.8×	460 1.2×	159 0.6×	76	2.4k
Marja K. Pasanen Finland	13	1.2k 1.5×	699 1.0×	273 0.5×	754 2.0×	107 0.4×	16	2.1k
Bennett Ma United States	16	467 0.6×	489 0.7×	356 0.6×	616 1.6×	123 0.5×	38	1.6k
Teddy Kosoglou United States	26	352 0.4×	890 1.3×	194 0.3×	213 0.6×	210 0.8×	65	2.2k
Ron HN van Schaik Netherlands	31	780 1.0×	447 0.6×	583 1.0×	1.2k 3.2×	91 0.3×	92	3.2k
Ulf G. Eriksson Sweden	30	379 0.5×	564 0.8×	447 0.8×	399 1.0×	63 0.2×	103	3.2k
David Jones United States	29	819 1.0×	217 0.3×	792 1.4×	679 1.8×	79 0.3×	58	2.4k
Hideki Fujino Japan	20	579 0.7×	377 0.5×	153 0.3×	508 1.3×	75 0.3×	36	1.1k
Richard Ho United States	23	1.2k 1.5×	617 0.9×	416 0.7×	428 1.1×	48 0.2×	58	2.5k
Danièle Ouellet United States	31	1.3k 1.6×	171 0.2×	1.4k 2.5×	318 0.8×	70 0.3×	93	3.3k

Countries citing papers authored by Paul Martin

Since Specialization

Citations

This map shows the geographic impact of Paul Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Martin more than expected).

Fields of papers citing papers by Paul Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Martin. The network helps show where Paul Martin may publish in the future.

Co-authorship network of co-authors of Paul Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Martin. A scholar is included among the top collaborators of Paul Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Martin. Paul Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gorycki, Peter D., et al.. (2024). Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters. Clinical and Translational Science. 17(4). e13799–e13799. 3 indexed citations

Bruckmueller, Henrike, Paul Martin, Sierk Haenisch, et al.. (2017). Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine. Molecular Pharmaceutics. 14(7). 2245–2253. 29 indexed citations

Elks, Cathy E., Paul Martin, David Carlile, et al.. (2017). Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology. 73(6). 717–726. 12 indexed citations

Tomkinson, Helen, Eileen McBride, Paul Martin, et al.. (2017). Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects. Clinical Therapeutics. 39(11). 2260–2275.e1. 12 indexed citations

Martin, Paul, Michael Gillen, David Millson, et al.. (2016). Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies. Drugs in R&D. 16(1). 81–92. 15 indexed citations

Martin, Paul, et al.. (2016). Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects. The Journal of Clinical Pharmacology. 57(5). 592–605. 15 indexed citations

Zhou, Diansong, Karen So, Nidal Al‐Huniti, et al.. (2016). Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Clinical Therapeutics. 38(12). 2555–2566. 3 indexed citations

Elsby, Robert, Paul Martin, Dominic Surry, Pradeep Sharma, & Katherine S. Fenner. (2015). Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug Metabolism and Disposition. 44(3). 398–408. 81 indexed citations

Macpherson, M., Bengt Hamrén, Marjet J.A.M. Braamskamp, et al.. (2015). Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. European Journal of Clinical Pharmacology. 72(1). 19–27. 7 indexed citations

10.

Martin, Paul, S.Y. Amy Cheung, Mark Yen, David Han, & Michael Gillen. (2015). Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies. European Journal of Clinical Pharmacology. 72(1). 61–71. 9 indexed citations

11.

Langslet, Gisle, Marjet J.A.M. Braamskamp, Brian W. McCrindle, et al.. (2014). EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY. Journal of the American College of Cardiology. 63(12). A1288–A1288.

12.

Johansson, Susanne, Jessica Read, Stuart Oliver, et al.. (2014). Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine. Clinical Pharmacokinetics. 53(9). 837–847. 52 indexed citations

13.

Martin, Paul, et al.. (2008). The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Current Medical Research and Opinion. 24(4). 1231–1235. 16 indexed citations

14.

Davies, Barry R., Armelle Logié, Jennifer S. McKay, et al.. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Molecular Cancer Therapeutics. 6(8). 2209–2219. 322 indexed citations

15.

Logié, Armelle, et al.. (2005). Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model. Cancer Research. 65. 1409–1409. 2 indexed citations

16.

Simonson, Steven G., et al.. (2003). Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. European Journal of Clinical Pharmacology. 58(10). 669–675. 52 indexed citations

17.

Martin, Paul. (2003). Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clinical Therapeutics. 25(10). 2553–2563. 169 indexed citations

18.

Cooper, Kevin D., Paul Martin, Aaron Dane, et al.. (2002). The effect of fluconazole on the pharmacokinetics of rosuvastatin. European Journal of Clinical Pharmacology. 58(8). 527–531. 92 indexed citations

19.

Martin, Paul, John Kemp, Aaron Dane, Mike J. Warwick, & Dennis W. Schneck. (2002). No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology. 42(12). 1352–1357. 42 indexed citations

20.

Duffner, Patricia K., Peter C. Burger, Michael E. Cohen, et al.. (1994). Desmoplastic Infantile Gangliogliomas. Neurosurgery. 34(4). 583–589. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact